NCT04897035: A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Dayspring Active Wearable Compression Technology for Treating Lower Extremity Lymphedema

NCT04897035
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have diagnosis of lower extremity edema (swelling); Patients must be at least 3 months post surgery, chemotherapy and/or radiation treatment for cancer
Exclusions: 
https://ClinicalTrials.gov/show/NCT04897035

Comments are closed.

Up ↑